HealthNEWSLETTER: AstraZeneca drug reduces lung disease flare-ups in late-stage trials

The newsletter highlights data from studies presented at the ongoing European Respiratory Society Congress in Barcelona, including findings that an AstraZeneca drug reduced lung disease flare-ups in late-stage trials.

AstraZenecalung diseaseclinical trialsEuropean Respiratory Society Congress

RReuters★★☆☆☆2026-09-09 15:05Original